Medifast (NYSE: MED) reported Q4 EPS of $1.30, $0.09 better than the analyst estimate of $1.21. Revenue for the quarter came in at $145.8 million versus the consensus estimate of $142.86 million.

• Revenue of $145.8 million, an increase of 87.0% year-over-year
• Active earning Coaches of 24,100, an increase of 60.7% year-over-year
• Net income of $15.7 million, an increase of 114.2% year-over-year
• Earnings per diluted share ("EPS") of $1.30, an increase of 116.7% year-over-year

"We are very pleased with our strong finish to 2018," commented Dan Chard, Medifast's Chief Executive Officer. "We reached a significant corporate milestone generating over $500 million in annual revenue and profitability exceeded our expectations. Importantly, we achieved these results while accelerating the level of strategic investment to support our long-term growth plans to build our brand platform and operations as we continue to improve the scalability of our business. As we move forward with our strategic initiatives, both domestically and internationally, we believe we remain well positioned to deliver long-term sustainable growth and value for our shareholders as well as meaningful improvements to the lives of OPTAVIA clients across the country as they learn new healthy habits that make their lives better."

GUIDANCE:

Medifast sees Q1 2019 EPS of $1.50-$1.55, versus the consensus of $1.45. Medifast sees Q1 2019 revenue of $150-155 million, versus the consensus of $149.65 million.

Medifast sees FY2019 EPS of $6.45-$6.65, versus the consensus of $5.99. Medifast sees FY2019 revenue of $700-720 million, versus the consensus of $663.1 million.

For earnings history and earnings-related data on Medifast (MED) click here.